Kringle Pharma, Inc. (TYO:4884)
501.00
-73.00 (-12.72%)
Nov 18, 2026, 10:39 AM JST
Kringle Pharma Revenue
In the fiscal year ending September 30, 2026, Kringle Pharma had annual revenue of 442.00M JPY with 513.89% growth. Kringle Pharma had revenue of 118.11M in the quarter ending September 30, 2026, with 552.30% growth. That makes Kringle Pharma the 41,691st largest company in the world by revenue and 3,848th in Japan.
Revenue
442.00M
Revenue Growth
+513.89%
P/S Ratio
10.89
Revenue / Employee
n/a
Employees
17
Market Cap
4.20B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2026 | 442.00M | 370.00M | 513.89% |
| Sep 30, 2025 | 72.00M | -8.00M | -10.00% |
| Sep 30, 2024 | 80.00M | 11.00M | 15.94% |
| Sep 30, 2023 | 69.00M | -322.00M | -82.35% |
| Sep 30, 2022 | 391.00M | 102.00M | 35.29% |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Soiken Holdings | 3.87B |
| CellSource | 3.67B |
| MEDINET | 998.00M |
| PRISM BioLab Co.,LTD | 737.27M |
| SUSMED,Inc. | 679.00M |
| Chiome Bioscience | 615.15M |
| Cyfuse Biomedical K.K. | 305.00M |
| Nano Holdings | 202.00M |